Observational Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2020; 8(12): 2542-2553
Published online Jun 26, 2020. doi: 10.12998/wjcc.v8.i12.2542
Real-time three-dimensional echocardiography predicts cardiotoxicity induced by postoperative chemotherapy in breast cancer patients
Fang Zhou, Lin Niu, Min Zhao, Wei-Xing Ni, Jian Liu
Fang Zhou, Jian Liu, Department of Breast Surgery, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China
Lin Niu, Min Zhao, Wei-Xing Ni, Department of Ultrasound, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China
Author contributions: Zhou F and Niu L contributed equally to this study; Zhou F, Niu L, and Zhao M designed the research; Zhou F, Niu L, Zhao M, Ni WX, and Liu J performed the research; Ni WX and Liu J contributed new analytic tools; Zhou F, Niu L, Ni WX, and Liu J analyzed the data; Zhou F, Niu L, and Zhao M wrote the paper.
Supported by Medical and Health Foundation Project of Zhejiang Province, China, No. 2020KY690; and Natural Science Foundation of Zhejiang Province, China, No. LGF20H020004.
Institutional review board statement: This study was approved by the ethics committee of Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine.
Informed consent statement: All patients gave informed consent.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Min Zhao, MD, Deputy Chief Physician, Department of Ultrasound, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, No. 261, Huansha Road, Hangzhou 310006, Zhejiang Province, China. hzzhaomin@126.com
Received: February 24, 2020
Peer-review started: February 24, 2020
First decision: March 27, 2020
Revised: April 1, 2020
Accepted: June 2, 2020
Article in press: June 2, 2020
Published online: June 26, 2020
Core Tip

Core tip: Although chemotherapeutics can improve the curative effect of breast cancer, there is a certain degree of cardiotoxicity. The patient's cardiac function needs to be closely monitored during chemotherapy. Studies have found that left ventricular diastolic dysfunction can indicate early cardiac impairment. Therefore, the analysis of left ventricular diastolic function to evaluate the cardiac toxicity is the research focus. However, the current indicators can only prove that they are related to cardiotoxicity, but they cannot early predict the occurrence of cardiotoxicity. In this study, RT3DE was used to measure the left atrial volume, and it was found that the left atrial volume index was the most accurate in predicting the cardiotoxicity caused by chemotherapy in the early stage.